NBI-98854
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
The vesicular monoamine transporter 2 (VMAT2) is an integral presynaptic protein that regulates the packaging and subsequent…
The objective of this systematic review was to describe the efficacy, tolerability, and safety of valbenazine for the treatment…
OBJECTIVE
Tardive dyskinesia is a persistent movement disorder induced by dopamine receptor blockers, including antipsychotics…
BACKGROUND
Valbenazine (VBZ, NBI-98854) is a novel vesicular monoamine transporter 2 (VMAT2) inhibitor approved for the treatment…
BACKGROUND
The short-term safety profile of once-daily valbenazine (NBI-98854) has been evaluated in several double-blind…
BACKGROUND
Valbenazine (VBZ, NBI-98854) is a novel vesicular monoamine transporter 2 (VMAT2) inhibitor approved for the treatment…
Objective: To characterize the pharmacology of valbenazine and its metabolites in vitro . Background: Valbenazine (NBI-98854), a…
Objective:
To assess the efficacy, safety and tolerability of valbenazine (NBI-98854) for Tardive Dyskinesia (TD).
Background…
Tardive dyskinesia is a persistent movement disorder induced by chronic neuroleptic exposure. NBI‐98854 is a novel, highly…